Producers can take respiratory protection to the next level
NEW YORK — Sept. 27, 2010 — Pfizer Animal Health announces enhanced respiratory protection for Bovi-Shield GOLD® 5.* This trusted vaccine is now labeled to prevent respiratory disease caused by infectious bovine rhinotracheitis (IBR) with at least a nine-month duration of immunity. Bovi-Shield GOLD 5 also offers an extended duration of immunity for bovine viral diarrhea (BVD) Types 1 and 2 of at least nine months.
“Producers can rest assured that Bovi-Shield GOLD is working to help protect cattle from respiratory disease during critical disease exposure points,” says Michael Nichols, DVM, Veterinary Operations, Pfizer Animal Health. “Stressed cattle are more susceptible to disease challenges. That’s why it is so valuable to vaccinate cattle prior to these challenges with a product that has an extended duration of immunity and promises to help prevent respiratory disease.”
Bovi-Shield GOLD 5 is the first and only vaccine that is approved to prevent IBR respiratory disease for at least nine months when administered by the subcutaneous route. In addition, it is the only vaccine that aids in the prevention of respiratory disease caused by BVD Types 1 and 2 for at least nine months when administered by the subcutaneous route.
“When it comes to IBR and BVD, most vaccines aren’t labeled for a specific duration of immunity,” Dr. Nichols says. “For those that are, the best offer at least 182 days and 206 days of protection, respectively. This may not be sufficient to help protect beef calves from branding to weaning or during an extended feeding period — or to help protect dairy heifers until they receive their first reproductive vaccines before breeding.”
A highly contagious disease, IBR is one of the most common virus infections in cattle in the U.S. and has been found in all areas of the country. In fact, IBR and BVD Types 1 and 2 are leading causes of bovine respiratory disease (BRD) — a disease costing the beef industry up to $1 billion annually from death, reduced feed efficiency and treatment costs.1
In addition to IBR and BVD Types 1 and 2, bovine respiratory syncytial virus (BRSV) and parainfluenza type 3 (PI3) also can help open the door to secondary bacterial infections that may lead to BRD, adds Dr. Nichols.2
In fact, according to 2007 National Animal Health Monitoring System data, bovine respiratory disease — commonly known as pneumonia in the dairy industry — is the second leading cause of death in heifer calves prior to weaning (22.5 percent of deaths) and the leading cause of death of weaned heifers (46.5 percent of all deaths).3
“Producers should be careful to choose a vaccine that helps protect against viral agents that can lead to BRD,” Dr. Nichols says. “Bovi-Shield GOLD 5 now provides a nine-month duration of immunity against respiratory disease caused by BVD Types 1 and 2 and IBR, and has demonstrated an ability to prevent respiratory disease caused by IBR. Bovi-Shield GOLD 5 also helps protect against BRSV and PI3. Combined, these label claims will help producers save time and money in the long run.”
Pfizer Animal Health, a business of Pfizer Inc., is a world leader in discovering and developing innovative animal prescription medicines and vaccines, investing an estimated $300 million annually. Beyond the U.S., Pfizer Animal Health also supports veterinarians and their customers in more than 60 countries around the world. For more information on how Pfizer Animal Health works to ensure a safe, sustainable global food supply with healthy livestock and poultry, or how Pfizer Animal Health helps companion animals and horses to live longer, healthier lives, visit www.pfizerah.com.